Wolfe Research slashes price target on Edwards Lifesciences Corporation [EW] – find out why.

Edwards Lifesciences Corporation [NYSE: EW] closed the trading session at $85.24 on 11/19/20. The day’s price range saw the stock hit a low of $84.07, while the highest price level was $85.5447. The company report on October 22, 2020 that Edwards Lifesciences Corp. to Host Earnings Call.

Edwards Lifesciences Corp. (NYSE:EW) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on October 21, 2020 at 5:00 PM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/event/presentation/68367.

The stocks have a year to date performance of 9.61 percent and weekly performance of 6.09 percent. The stock has been moved at 16.87 percent over the last six months. The stock has performed 1.95 percent around the most recent 30 days and changed 8.30 percent over the most recent 3-months.

If compared to the average trading volume of 2.67M shares, EW reached to a volume of 2158298 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Edwards Lifesciences Corporation [EW]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EW shares is $89.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EW stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wolfe Research have made an estimate for Edwards Lifesciences Corporation shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on September 11, 2020. While these analysts kept the previous recommendation, Wells Fargo dropped their target price from $250 to $230. The new note on the price target was released on April 28, 2020, representing the official price target for Edwards Lifesciences Corporation stock. Previously, the target price had yet another raise to $270, while SVB Leerink analysts kept a Outperform rating on EW stock.

The Average True Range (ATR) for Edwards Lifesciences Corporation is set at 2.81, with the Price to Sales ratio for EW stock in the period of the last 12 months amounting to 11.95. The Price to Book ratio for the last quarter was 12.59, with the Price to Cash per share for the same quarter was set at 2.12. Price to Free Cash Flow for EW in the course of the last twelve months was 75.82 with Quick ratio for the last quarter at 2.60.

EW stock trade performance evaluation

Edwards Lifesciences Corporation [EW] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.09. With this latest performance, EW shares gained by 1.95% in over the last four-week period, additionally plugging by 16.87% over the last 6 months – not to mention a rise of 4.70% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EW stock in for the last two-week period is set at 64.09, with the RSI for the last a single of trading hit 68.54, and the three-weeks RSI is set at 59.06 for Edwards Lifesciences Corporation [EW]. The present Moving Average for the last 50 days of trading for this stock 80.38, while it was recorded at 83.92 for the last single week of trading, and 74.49 for the last 200 days.

Edwards Lifesciences Corporation [EW]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Edwards Lifesciences Corporation [EW] shares currently have an operating margin of +27.55 and a Gross Margin at +73.43. Edwards Lifesciences Corporation’s Net Margin is presently recorded at +24.08.

Return on Total Capital for EW is now 27.98, given the latest momentum, and Return on Invested Capital for the company is 24.53. Return on Equity for this stock inclined to 28.73, with Return on Assets sitting at 17.73. When it comes to the capital structure of this company, Edwards Lifesciences Corporation [EW] has a Total Debt to Total Equity ratio set at 16.36. Additionally, EW Total Debt to Total Capital is recorded at 14.06, with Total Debt to Total Assets ending up at 10.46. Long-Term Debt to Equity for the company is recorded at 15.75, with the Long-Term Debt to Total Capital now at 13.53.

Reflecting on the efficiency of the workforce at the company, Edwards Lifesciences Corporation [EW] managed to generate an average of $75,317 per employee. Receivables Turnover for the company is 7.65 with a Total Asset Turnover recorded at a value of 0.74.Edwards Lifesciences Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 3.50.

Earnings per share (EPS) analysis for Edwards Lifesciences Corporation [EW] stock

With the latest financial reports released by the company, Edwards Lifesciences Corporation posted 0.49/share EPS, while the average EPS was predicted by analysts to be reported at 0.49/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EW. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Edwards Lifesciences Corporation go to 12.14%.

Edwards Lifesciences Corporation [EW]: Insider Ownership positions

There are presently around $44,239 million, or 87.30% of EW stock, in the hands of institutional investors. The top three institutional holders of EW stocks are: BLACKROCK INC. with ownership of 59,037,509, which is approximately -0.684% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 48,841,226 shares of the stock with an approximate value of $4.16 billion in EW stocks shares; and STATE STREET CORP, currently with $2.28 billion in EW stock with ownership of nearly -1.81% of the company’s market capitalization.

Positions in Edwards Lifesciences Corporation stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 506 institutional holders increased their position in Edwards Lifesciences Corporation [NYSE:EW] by around 33,322,813 shares. Additionally, 463 investors decreased positions by around 25,976,382 shares, while 187 investors held positions by with 459,689,165 shares. The mentioned changes placed institutional holdings at 518,988,360 shares, according to the latest SEC report filing. EW stock had 119 new institutional investments in for a total of 9,102,115 shares, while 81 institutional investors sold positions of 2,416,522 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam